William S. Sievert

Family Medicine

11855 Ulysses St NE
Minneapolis, MN 55434

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 86 publications

Differing Epidemiology of Chronic Hepatitis C Infection, Treatment, and Outcomes Among Migrants and Australian-Born Patients.

Differing Epidemiology of Chronic Hepatitis C Infection, Treatment, and Outcomes Among Migrants and Australian-Born Patients.

Journal: Journal of viral hepatitis

Published: May 20, 2026

Five-year outcomes of a dedicated, multidisciplinary clinic for decompensated cirrhosis.

Five-year outcomes of a dedicated, multidisciplinary clinic for decompensated cirrhosis.

Journal: Internal medicine journal

Published: June 18, 2025

Surviving Hepatitis C-Understanding Death and Survival Beyond Cure.

Surviving Hepatitis C-Understanding Death and Survival Beyond Cure.

Journal: Alimentary pharmacology & therapeutics

Published: February 05, 2025

A Nonrandomized Pilot Study to Investigate the Acceptability and Feasibility of LivR Well: A Multifaceted 28-Day Home-Based Liver Optimization Program for Acute-on-Chronic Liver Failure.

A Nonrandomized Pilot Study to Investigate the Acceptability and Feasibility of LivR Well: A Multifaceted 28-Day Home-Based Liver Optimization Program for Acute-on-Chronic Liver Failure.

Journal: Gastro hep advances

Published: July 29, 2024

Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study (OPERA-C).

Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study (OPERA-C).

Journal: Drug and alcohol review

Published: February 13, 2024

High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy.

High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: January 06, 2024

Time-Restricted Fasting Improves Liver Steatosis in Non-Alcoholic Fatty Liver Disease-A Single Blinded Crossover Trial.

Time-Restricted Fasting Improves Liver Steatosis in Non-Alcoholic Fatty Liver Disease-A Single Blinded Crossover Trial.

Journal: Nutrients

Published: October 13, 2023

Human Amniotic Epithelial Cell Transplantation is Safe and Well Tolerated in Patients with Compensated Cirrhosis: A First-in-Human Trial.

Human Amniotic Epithelial Cell Transplantation is Safe and Well Tolerated in Patients with Compensated Cirrhosis: A First-in-Human Trial.

Journal: Stem cells translational medicine

Published: August 05, 2023

Local fistula injection of allogeneic human amnion epithelial cells is safe and well tolerated in patients with refractory complex perianal Crohn's disease: a phase I open label study with long-term follow up.

Local fistula injection of allogeneic human amnion epithelial cells is safe and well tolerated in patients with refractory complex perianal Crohn's disease: a phase I open label study with long-term follow up.

Journal: EBioMedicine

Published: July 31, 2023

Broadening and strengthening the health providers caring for patients with chronic hepatitis C may improve continuity of care.

Broadening and strengthening the health providers caring for patients with chronic hepatitis C may improve continuity of care.

Journal: Journal of gastroenterology and hepatology

Published: July 13, 2023

First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection.

First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection.

Journal: Journal of hepatology

Published: January 04, 2023

Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants.

Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants.

Journal: Hepatology communications

Published: December 06, 2022

Showing 1-12 of 86

Last Updated: 09/26/2026